Component

Dietary phenylalanine tolerance in responsive PKU children

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. In 46 preselected sapropterin-responsive children, 20 mg/kg/day allowed more supplemental dietary phenylalanine while maintaining study blood targets: 20.9 versus 2.9 mg/kg/day with placebo.

    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Ten-week randomized trial after responder selection.
    limitations
    Selected pediatric responders cannot represent all PKU patients.
    nutrient_topic
    L-Phenylalanine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · L-Phenylalanine
    plain_language
    When processing capacity improves, a responsive patient may tolerate more dietary phenylalanine.
    primary_references
    Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19261295/ · DOI 10.1016/j.jpeds.2008.11.040

    L-Phenylalanine: transport, protein synthesis, cofactor recycling and cross-nutrient mechanisms (2026-09-19) · lines 230–236

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Ten-week randomized trial after responder selection. · source_derived_draft · unverified_draft

    ## l-phenylalanine-sapropterin-tolerance When processing capacity improves, a responsive patient may tolerate more dietary phenylalanine. In 46 preselected sapropterin-responsive children, 20 mg/kg/day allowed more supplemental dietary phenylalanine while maintaining study blood targets: 20.9 versus 2.9 mg/kg/day with placebo. Model: Ten-week randomized trial after responder selection. Limitations: Selected pediatric responders cannot represent all PKU patients. Evidence access: Primary abstract Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19261295/ · DOI 10.1016/j.jpeds.2008.11.040
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards